Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVACNASDAQ:CYTKNASDAQ:KRYSNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$5.57-0.5%$3.76$2.37▼$5.72$1.25B2.49800,115 shs4.83 million shsCYTKCytokinetics$34.38+3.6%$34.83$29.31▼$61.38$4.11B0.591.56 million shs1.60 million shsKRYSKrystal Biotech$137.07-2.3%$146.57$122.80▼$219.34$3.96B0.65304,066 shs295,086 shsRNAAvidity Biosciences$31.37-2.4%$29.99$21.51▼$56.00$3.78B0.951.41 million shs963,594 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac0.00%+26.30%+62.87%+85.05%+34.22%CYTKCytokinetics0.00%+6.44%+15.21%-22.50%-36.38%KRYSKrystal Biotech0.00%+0.09%+5.17%-23.59%-24.67%RNAAvidity Biosciences0.00%-13.44%+8.28%+0.84%-18.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac4.3543 of 5 stars3.34.00.04.83.00.01.3CYTKCytokinetics4.2638 of 5 stars4.53.00.04.61.90.80.0KRYSKrystal Biotech4.538 of 5 stars3.51.00.04.73.52.51.9RNAAvidity Biosciences2.0832 of 5 stars4.50.00.00.02.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 2.67Moderate Buy$9.0061.58% UpsideCYTKCytokinetics 2.93Moderate Buy$70.92106.29% UpsideKRYSKrystal Biotech 3.00Buy$211.1354.03% UpsideRNAAvidity Biosciences 3.07Buy$67.33114.64% UpsideCurrent Analyst Ratings BreakdownLatest CVAC, CYTK, RNA, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/11/2025RNAAvidity BiosciencesRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$65.006/10/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $75.006/10/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/10/2025RNAAvidity BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.006/9/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.006/9/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $75.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$523.70M2.39N/AN/A$2.50 per share2.23CYTKCytokinetics$19.22M213.65N/AN/A($3.94) per share-8.73KRYSKrystal Biotech$333.45M11.88$3.48 per share39.38$32.85 per share4.17RNAAvidity Biosciences$8.93M423.51N/AN/A$6.76 per share4.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac-$281.58M$0.9210.13N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)CYTKCytokinetics-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%8/6/2025 (Estimated)KRYSKrystal Biotech$10.93M$4.1645.8413.60N/A30.69%11.41%10.40%8/4/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$3.00N/AN/AN/A-2,772.45%-27.66%-24.56%8/8/2025 (Estimated)Latest CVAC, CYTK, RNA, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.206.19CYTKCytokinetics5.939.289.28KRYSKrystal BiotechN/A7.287.76RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCVACCureVac2.15%CYTKCytokinetics2.70%KRYSKrystal Biotech13.70%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.07 millionOptionableCYTKCytokinetics250119.43 million114.00 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableRNAAvidity Biosciences190120.52 million114.92 millionOptionableCVAC, CYTK, RNA, and KRYS HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 15 at 4:24 AM | marketbeat.comRhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14 at 3:32 AM | marketbeat.comGAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14 at 3:18 AM | marketbeat.comLeerink Partnrs Analysts Decrease Earnings Estimates for RNAJune 14 at 2:17 AM | americanbankingnews.comW. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 12 at 8:41 PM | marketbeat.comLeerink Partnrs Has Pessimistic View of RNA FY2026 EarningsJune 12 at 8:49 AM | marketbeat.comRaymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy RecommendationJune 12 at 6:19 AM | msn.comBarclays Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) StockJune 12 at 2:20 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Citigroup Analyst SaysJune 12 at 2:20 AM | americanbankingnews.comAnalysts Offer Predictions for RNA FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comAvidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond JamesJune 11, 2025 | msn.comAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressJune 11, 2025 | prnewswire.comCantor Fitzgerald Weighs in on RNA FY2026 EarningsJune 11, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock PriceJune 11, 2025 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Price Target Raised to $54.00 at Bank of AmericaJune 11, 2025 | americanbankingnews.com1RNA : The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 ExpertsJune 10, 2025 | benzinga.comCitigroup Increases Avidity Biosciences (NASDAQ:RNA) Price Target to $75.00June 10, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Barclays Analyst SaysJune 10, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJune 10, 2025 | marketbeat.comAvidity Biosciences stock falls following positive trial dataJune 10, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsCVAC, CYTK, RNA, and KRYS Company DescriptionsCureVac NASDAQ:CVAC$5.57 -0.03 (-0.54%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.60 +0.03 (+0.54%) As of 06/13/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Cytokinetics NASDAQ:CYTK$34.38 +1.18 (+3.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.28 -0.10 (-0.29%) As of 06/13/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$137.07 -3.26 (-2.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$137.08 +0.01 (+0.01%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Avidity Biosciences NASDAQ:RNA$31.37 -0.77 (-2.40%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$31.36 -0.02 (-0.05%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
